Abstracts tagged "pediatric rheumatology and tocilizumab"

Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Kamal N. Bharucha¹, Hermine I. Brunner², Nicola Ruperto³, David A. Cabral², Abraham Gedalia², Valeria Gerloni³, Christian Jorgensen³, Athimalaipet Ramanan³, Daniel Lovell², Alberto Martini⁴, James Frane⁵, Chris Wells⁶ and Fabrizio De Benedetti Sr.⁷, ¹Genentech, South San Francisco, CA, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Consultant, Santa Monica, CA, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…
Abstract Number: 1597 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase 3 Trial
Hermine Brunner¹, Nicolino Ruperto², Zbigniew Zuber³, Caroline Keane⁴, Olivier Harari⁵, Andrew Kenwright⁴, Rubén J. Cuttica⁶, Vladimir Keltsev⁷, Ricardo Xavier³, Inmaculada Calvo Penades⁷, Irina Nikishina⁸, Nadina Rubio-Perez⁹, Ekaterina Alekseeva¹⁰, Vyacheslav Chasnyk¹¹, Jose Chavez³, Gerd Horneff¹², Violetta Opoka-Winiarska³, Pierre Quartier¹³, Clovis A. Silva⁷, Earl D. Silverman¹⁴, Alberto Spindler¹⁴, D. J. Lovell¹⁵, Alberto Martini¹⁴ and Fabrizio De Benedetti¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³PRINTO, Genoa, Italy, ⁴Roche, Welwyn Garden City, United Kingdom, ⁵Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genoa, Italy, ⁸Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁹Hospital Universitario Dr. José Eleuterio Gonzalez, Monterrey, Mexico, ¹⁰Istituto Giannina Gaslini, Genoa, Italy, ¹¹Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ¹²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ¹³Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ¹⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹⁵Cincinnati Children's Hospital, Cincinnati, OH, ¹⁶PRINTO and PRSCG, Genoa, Italy
Background/Purpose: Elevated IL-6 levels are associated with disease activity in patients (pts) with juvenile idiopathic arthritis (JIA).1 Tocilizumab (TCZ), an IL-6 receptor inhibitor, was evaluated…
Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting
Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial
Fabrizio De Benedetti¹, Nicolino Ruperto², Graciela Espada³, Valeria Gerloni⁴, Berit Flato⁵, Gerd Horneff⁶, Barry L. Myones⁷, Karen Onel⁸, James Frane⁹, Andrew Kenwright¹⁰, Terri H. Lipman¹¹, Kamal N. Bharucha⁹, Alberto Martini⁷ and D. J. Lovell¹², ¹Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ⁴Istituto Gaetano Pini, Milan, Italy, ⁵Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁶Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ⁷Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁸PRCSG, Cincinnati, OH, ⁹Genentech, South San Francisco, CA, ¹⁰Roche, Welwyn Garden City, United Kingdom, ¹¹University of Pennsylvania School of Nursing, Philadelphia, PA, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].